TY - JOUR
T1 - Interferon-β-1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection
AU - Clementi, Nicola
AU - Ferrarese, Roberto
AU - Criscuolo, Elena
AU - Diotti, Roberta Antonia
AU - Castelli, Matteo
AU - Scagnolari, Carolina
AU - Burioni, Roberto
AU - Antonelli, Guido
AU - Clementi, Massimo
AU - Mancini, Nicasio
N1 - Funding Information:
We thank Dan McAuley for revising the English in the manuscript
Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) β-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.
AB - The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) β-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.
KW - COVID-19 clinical trial
KW - IFN-β-1a
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85089128223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089128223&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiaa350
DO - 10.1093/infdis/jiaa350
M3 - Article
C2 - 32559285
AN - SCOPUS:85089128223
VL - 222
SP - 722
EP - 725
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -